Global Patent Index - EP 4037690 A1

EP 4037690 A1 20220810 - COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST

Title (en)

COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST

Title (de)

KOMBINATIONSTHERAPIE MIT EINEM HEMMER DER INTERLEUKIN-17-AKTIVITÄT UND EINEM VITAMIN-D-REZEPTORAGONISTEN

Title (fr)

POLYTHÉRAPIE COMPRENANT UN INHIBITEUR DE L'ACTIVITÉ DE L'INTERLEUKINE-17 ET UN AGONISTE DU RÉCEPTEUR DE LA VITAMINE D

Publication

EP 4037690 A1 20220810 (EN)

Application

EP 20785714 A 20200929

Priority

  • EP 19382836 A 20190930
  • EP 2020077227 W 20200929

Abstract (en)

[origin: EP3797779A1] The invention relates to a combined therapy including an inhibitor of interleukin-17 (IL-17) activity for use in combination with a vitamin D receptor agonist in the prevention and/or treatment of diseases or conditions known as autoimmune and autoinflammatory concomitant diseases, such as autoimmune kidney diseases, autoimmune joint diseases, skin autoimmune diseases, autoimmune neurological diseases, autoimmune thyroid diseases, and gout disease. The invention provides also the combination for use in the treatment and/or prevention of cancer, in which deregulation of immune system takes place. The invention also relates to the therapeutic combination and to its use in the treatment or prevention of proteinuria.

IPC 8 full level

A61K 31/59 (2006.01); A61K 39/00 (2006.01); A61P 13/12 (2006.01)

CPC (source: EP)

A61K 31/592 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 13/12 (2018.01); C07K 16/244 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01)

C-Set (source: EP)

  1. A61K 31/592 + A61K 2300/00
  2. A61K 39/3955 + A61K 2300/00

Citation (examination)

  • SABNIS RAM W.: "Imidazo[1,2- b ]pyridazines as IL-17A Inhibitors for Treating Psoriasis, Rheumatoid Arthritis, and Multiple Sclerosis", ACS MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 10, 13 September 2021 (2021-09-13), US, pages 1526 - 1527, XP055958394, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.1c00470
  • LIU X ET AL: "Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 386, no. 1, 14 August 2009 (2009-08-14), pages 181 - 185, XP026467441, ISSN: 0006-291X, [retrieved on 20090607], DOI: 10.1016/J.BBRC.2009.06.008
  • DURAKOVIC C ET AL: "Topical paricalcitol (19-nor-1[alpha],25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study", BRITISH JOURNAL OF DERMATOLOGY, JOHN WILEY, HOBOKEN, USA, vol. 151, no. 1, 9 July 2004 (2004-07-09), pages 190 - 195, XP071156810, ISSN: 0007-0963, DOI: 10.1111/J.1365-2133.2004.06002.X
  • See also references of WO 2021063945A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

EP 3797779 A1 20210331; EP 4037690 A1 20220810; WO 2021063945 A1 20210408

DOCDB simple family (application)

EP 19382836 A 20190930; EP 2020077227 W 20200929; EP 20785714 A 20200929